A Model of Cost-effectiveness of Tissue Plasminogen Activator in Patient Subgroups 3 to 4.5 Hours After Onset of Acute Ischemic Stroke

Annals of Emergency Medicine, 06/01/2012

The results indicate that recombinant tissue plasminogen activator in the 3– to 4.5–hour therapeutic window provides improvement in long–term patient outcomes in most patient subgroups and is a good economic value versus no treatment.

Print Article Summary Cat 2 CME Report